Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. announced that they have completed the rolling submission of a new drug application to the FDA, seeking priority review for vamorolone for the treatment of Duchenne muscular dystrophy.